Advertisement

Neurochemical Research

, Volume 28, Issue 8, pp 1145–1150 | Cite as

Amino Acids and Biogenic Amines in Cerebrospinal Fluid of Patients with Parkinson's Disease

  • S. Engelborghs
  • B. Marescau
  • P. P. De DeynEmail author
Article

Abstract

To study changes in amino acid metabolism and biogenic amines in Parkinson's disease, we set up a prospective study and measured biogenic amines, their main metabolites, and 22 different amino acids, in cerebrospinal fluid of Parkinson's disease patients (n = 24) and age-matched controls (n = 30). A trend toward higher dopamine levels in Parkinson's disease patients was interpreted as an effect of treatment with levodopa and/or selegiline. Significantly lower concentrations of the dopamine metabolite 3,4-dihydroxyphenylacetic acid in the Parkinson's disease group might reflect dopaminergic cell loss. Our results revealed decreased serotonin catabolism that was interpreted as an effect of treatment with selegiline. Whereas all amino acid levels were unchanged, taurine was significantly lower in Parkinson's disease patients. Studies showed that taurine exerts a trophic action on the central nervous system. In this view, decreased taurine in a neurodegenerative disorder as Parkinson's disease deserves attention.

Parkinson's disease amino acids biogenic amines taurine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. 1.
    Molina, J. A., Jiménez-Jiménez, F. J., Gómez, P., Vargas, C., Navarro, J. A., Orti-Pareja, M., Gasalla, T., Benito-Léon, J., Bermejo, F., and Arenas, J. 1997. Decreased cerebrospinal fluid levels of neutral and basic amino acids in patients with Parkinson's disease. J. Neurol. Sci. 150:123-127.Google Scholar
  2. 2.
    Lakke, J. P. and Teelken, A. W. 1976. Amino acid abnormalities in cerebrospinal fluid of patients with Parkinsonism and extrapyramidal disorders. Neurology 26:489-493.Google Scholar
  3. 3.
    Lakke, J. P., Teelken, A. W., van der Vloet, H., and Wolthers, B. G. 1987. Amino acid abnormalities in cerebrospinal fluid and blood serum of patients with Parkinson's disease, other heredodegenerative disorders and head injuries. Adv. Neurol. 45:243-247.Google Scholar
  4. 4.
    Hare, T. A., Beasley, B. L., Chambers, R. A., Boehme, D. H., and Vogel, W. H. 1973. DOPA and amino acid levels in plasma and cerebrospinal fluid of patients with Parkinson's disease before and during treatment with L-DOPA. Clin. Chim. Acta 45:273-280.Google Scholar
  5. 5.
    Araki, K., Takino, T., Ida, S., and Kuriyama, K. 1986. Alteration of amino acids in cerebrospinal fluid from patients with Parkinson's disease and spinocerebellar degeneration. Acta Neurol. Scand. 73:105-110.Google Scholar
  6. 6.
    van Sande, M., Caers, J., and Lowenthal, A. 1971. Cerebrospinal fluid amino acids in extrapyramidal disorders before and after L-DOPA treatment. Zeitschrift Neurol. 199:24-29.Google Scholar
  7. 7.
    Gjessing, L. R., Gjesdahl, P., Dietrichson, P., and Presthus, J. 1974. Free amino acids in the cerebrospinal fluid in old age and in Parkinson's disease. Eur. Neurol. 12:33-37.Google Scholar
  8. 8.
    Espino, A., Ambrosio, S., Bartrons, R., Bendahan, G., and Calopa, M. 1994. Cerebrospinal monoamine metabolites and amino acid content in patients with parkinsonian syndrome and rats lesioned with MPP+. J. Neural. Transm. 7:167-176.Google Scholar
  9. 9.
    Jiménez-Jiménez, F. J., Molina, J. A., Vargas, C., Gómez, P., Navarro, J. A., Benito-León, J., Ortí-Pareja, M., Gasalla, T., Cisneros, E., and Arenas, J. 1996. Neurotransmitter amino acids in cerebrospinal fluid of patients with Parkinson's disease. J. Neurol. Sci. 141:39-44.Google Scholar
  10. 10.
    Hare, T. A., Vanna, S., Beasley, B., Chambers, R., and Vogel, W. H. 1971. Amino acid and dopa levels in plasma and urine from L-dopa-treated patients with Parkinson's disease: J. Lab. Clin. Med. 77:319-325.Google Scholar
  11. 11.
    Iwasaki, Y., Ikeda, K., Shiojima, T., and Kinoshita, M. 1992. Increased plasma concentrations of aspartate, glutamate and glycine in Parkinson's disease. Neurosci. Lett. 145:175-177.Google Scholar
  12. 12.
    Tohgi, H., Abe, T., Hashiguchi, K., Takahashi, S., Nozaki, Y., and Kikuchi, T. 1991. A significant reduction of putative neurotransmitter amino acids in CSF of patients with Parkinson's disease and spinocerebellar degeneration. Neurosci. Lett. 126:155-158.Google Scholar
  13. 13.
    Mally, J., Szalai, G., and Stone, T. W. 1997. Changes in concentration of amino acids in serum and cerebrospinal fluid of patients with Parkinson's disease. J. Neurol. Sci. 151:159-162.Google Scholar
  14. 14.
    Zubenko, G. S., Marquis, J. K., Volicer, L., Direnfield, L. K., Langlais, P. J., Nixon, R. A. 1986. Cerebrospinal fluid levels of angiotensin converting enzyme, acetylcholinesterase, and dopamine metabolites in dementia associated with Alzheimer's disease and Parkinson's disease: A correlative study. Biol. Psychiatry 21:1365-1381.Google Scholar
  15. 15.
    Tohgi, H., Abe, T., Takahashi, S., Takahashi, J., and Hamato, H. 1993. Alterations in the concentration of serotonergic and dopaminergic substances in the cerebrospinal fluid of patients with Parkinson's disease and their changes after L-dopa administration. Neurosci. Lett. 159:135-138.Google Scholar
  16. 16.
    Eldrup, E., Mogensen, P., Jacobsen, J., Pakkenberg, H., and Christensen, N. J. 1995. CSF and plasma concentrations of free norepinephrine, dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC), 3,4-dihydroxyphenylalanine (DOPA), and epinephrine in Parkinson's disease. Acta Neurol. Scand. 92:116-121.Google Scholar
  17. 17.
    Scatton, B., Javoy-Agid, F., Rouquier, L., Dubois, B., and Agid, Y. 1983. Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res. 275:321-328.Google Scholar
  18. 18.
    Mena, M. A., Aguado, E. G., and De Yebenes, J. G. 1984. Monoamine metabolites in human cerebrospinal fluid. HPLC/ED method. Acta Neurol. Scand. 69:218-225.Google Scholar
  19. 19.
    Johansson, B. and Roos, B. E. 1969. 5-Hydroxyindoleacetic acid and homovanillic acid levels in the cerebrospinal fluid of health volunteers and patients with Parkinson's disease. Life Sci. 6:1449-1454.Google Scholar
  20. 20.
    LeWitt, P. A., Galloway, M. P., Matson, W., Milbury, P., Mc-Dermott, M., Srivastava, D. K., and Oakes, D. 1992. Markers of dopamine metabolism in Parkinson's disease. The Parkinson Study Group. Neurology 42:2111-2117.Google Scholar
  21. 21.
    Riederer, P., Birkmayer, W., Steemann, D., and Wuketich, S. 1977. Brain-noradrenaline and 3-methoxy-4-hydroxyphenylglycol in Parkinson's syndrome. J. Neural. Transm. 41:241-251.Google Scholar
  22. 22.
    Teychenne, P. F., Lake, C. R., and Ziegler, M. G. 1980. Cerebrospinal fluid studies in Parkinson's disease. Pages 197-206, in Wood, J. H. (ed.), Neurobiology of cerebrospinal fluid, Plenum Press, New York.Google Scholar
  23. 23.
    Chan-Palay, V. and Asan, E. 1989. Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without dementia and depression. J. Comp. Neurol. 287:373-392.Google Scholar
  24. 24.
    Martignoni, E., Blandini, F., Petraglia, F., Pacchetti, C., Bono, G., and Nappi, G. 1992. Cerebrospinal fluid norepinephrine, 3-methoxy-4-hydroxyglycol and neuropeptide Y levels in Parkinson's disease, multiple system atrophy and dementia of the Alzheimer type. J. Neural. Transm. 4:191-205.Google Scholar
  25. 25.
    Turkka, J. T., Juujärvi, K. K., and Myllylä, V. V. 1987. Correlation of autonomic dysfunction to CSF concentrations of noradrenaline and 3-methoxy-4-hydroxyphenylglycol in Parkinson's disease. Eur Neurol. 26:29-34.Google Scholar
  26. 26.
    Chase, T. N. 1972. Serotonergic mechanisms in Parkinson's disease. Arch. Neurol. 27:354-356.Google Scholar
  27. 27.
    Hinterberger, H. and Andrews, C. J. 1972. Catecholamine metabolism during oral administration of levodopa. Arch. Neurol. 26:245-252.Google Scholar
  28. 28.
    Davidson, D. L., Yates, D. L., Mawdsley, C., Pullar, I. A., and Wilson, H. 1977. CSF studies on the relationship between dopamine and 5-hydroxytryptamine in parkinsonism and other movement disorders. J. Neurol. Neurosurg. Psychiatry, 40: 1136-1141.Google Scholar
  29. 29.
    Volicer, L., Direnfeld, L. K., Freedman, M., Albert, M. L., Langlais, P. J., and Bird, E. D. 1985. Serotonin and 5-hydroxy-indoleacetic acid in CSF. Difference in Parkinson's disease and dementia of the Alzheimer's type. Arch. Neurol. 42:127-129.Google Scholar
  30. 30.
    Pullar, I. A., Weddell, J. M., Ahmed, R., and Gillingham, F. J. 1970. Phenolic acid concentration in the lumbar cerebrospinal fluid of parkinsonian patients treated with L-Dopa. J. Neurol. Neurosurg. Psychiatry 33:851-857.Google Scholar
  31. 31.
    Van Woert, M. H. and Bowers, M. B. 1970. The effect of L-DOPA on monoamine metabolites in Parkinson's disease. Experientia 26:161-163.Google Scholar
  32. 32.
    Tohgi, H., Abe, T., Takahashi, S., Nozaki, Y., Ueno, M., and Kikuchi, T. 1992. Monoamine metabolism in the cerebrospinal fluid in Parkinson's disease: Relationship to clinical symptoms and subsequent therapeutic outcomes. J. Neural. Transm. P.D. Sect. 5:17-26.Google Scholar
  33. 33.
    Mayeux, R., Stern, Y., Sano, M., Williams, J. B., and Cote, L. J. 1988. The relationship of serotonin to depression in Parkinson's disease. Mov. Disord. 3:237-244.Google Scholar
  34. 34.
    Chan-Palay, V. 1993. Depression and dementia in Parkinson's disease: Catecholamine changes in the locus coeruleus, a basis for therapy. Adv. Neurol. 60:438-446.Google Scholar
  35. 35.
    Hoehn, M. M. and Yahr, M. D. 1967. Parkinsonism: Onset, progression and mortality. Neurology 17:427-442.Google Scholar
  36. 36.
    Pei, H. 1994. The use of cation exchange resin in analytical research of amino acids. Dissertation to obtain the degree of Master in Biomedical Sciences, University of Antwerp(U.I.A.), Belgium.Google Scholar
  37. 37.
    Folstein, M., Folstein, S., and McHugh, P. R. 1975. Mini-Mental State: A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12:189-196.Google Scholar
  38. 38.
    Tyce, G. M., Messick, J. M., Yaksh, T. L., Byer, D. E., Danielson, D. R., and Rorie, D. K. 1986. Amine sulfate formation in the central nervous system. Fed. Proc. 45:2247-2253.Google Scholar
  39. 39.
    Eldrup, E., Hagen, C., Christensen, N. J., and Ølgaard, K. 1988. Plasma free and sulfoconjugated dopamine in man: Relationship to sympathetic activity, adrenal function and meals. Dan. Med. Bull. 35:291-294.Google Scholar
  40. 40.
    Loeffler, D. A., LeWitt, P. A., Juneau, P. L., Camp, D. M., DeMaggio, A. J., Havaich, M. K., Milbury, P. E., and Matson, W. R. 1998. Influence of repeated levodopa administration on rabbit striatal serotonin metabolism and comparison between striatal and CSF alterations. Neurochem. Res. 23: 1521-1525.Google Scholar
  41. 41.
    Rozas, G., Liste, I., Guerra, M. J., and Labandeira-Garcia, J. L. 1998. Sprouting of serotonergic afferents into striatum after selective lesion of the dopaminergic system by MPTP in adult mice. Neurosci. Lett. 245:151-154.Google Scholar
  42. 42.
    Dawson, R. Jr., Pelleymounter, M. A., Cullen, M. J., Gollub, M., and Liu, S. 1999. An age-related decline in striatal taurine is correlated with a loss of dopaminergic markers. Brain Res. Bull. 48:319-324.Google Scholar
  43. 43.
    Kowall, N. W. and Beal, M. F. 1991. Glutamate-, glutaminase-, and taurine-immunoreactive neurons develop neurofibrillary tangles in Alzheimer's disease. Ann. Neurol. 29:162-167.Google Scholar
  44. 44.
    Alom, J., Mahy, J. N., Brandi, N., and Tolosa, E. 1991. Cerebrospinal fluid taurine in Alzheimer's disease. Ann. Neurol. 30:735.Google Scholar
  45. 45.
    Pomara, N., Singh, R., Deptula, D., Chou, J. C., Schwartz, M. B., and LeWitt, P. A. 1992. Glutamate and other CSF amino acids in Alzheimer's disease. Am. J. Psychiatry 149:251-254.Google Scholar

Copyright information

© Plenum Publishing Corporation 2003

Authors and Affiliations

  1. 1.Department of Neurology, Laboratory of Neurochemistry and Behavior, Born-Bunge FoundationUniversity of AntwerpBelgium
  2. 2.Department of Neurology and Memory ClinicMiddelheim General HospitalAntwerpBelgium

Personalised recommendations